P/E at 38.04 vs Industry's 36.83: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Premium Amidst Sector Norms

Sun Pharmaceutical Industries Ltd trades at a P/E of 38.04, slightly above the Pharmaceuticals & Biotechnology industry average of 36.83. This premium, while not extreme, suggests investors are willing to pay more for the company’s earnings relative to peers. The market capitalisation stands at a substantial ₹4,73,004.90 crores, underscoring its large-cap stature within the sector. Such a valuation premium often reflects confidence in the company’s earnings stability or growth prospects, but it also raises questions about whether the premium is justified given recent performance dynamics — previously rated Hold, what is Sun Pharmaceutical Industries Ltd’s current rating?

Performance Across Timeframes: A Mixed Momentum Story

The stock’s performance over various timeframes paints a picture of relative strength with some short-term fluctuations. Over the past year, Sun Pharmaceutical Industries Ltd has gained 16.31%, significantly outperforming the Sensex’s 4.89% decline. This outperformance extends to the three-month period, where the stock rose 12.80% compared to a marginal 0.06% gain in the Sensex. Year-to-date returns of 14.63% also highlight resilience amid broader market weakness, with the Sensex down 9.72% in the same period.

Shorter-term data shows a more cautious tone. The stock’s one-month return of 5.87% is positive but less pronounced, while the one-week gain of 0.47% contrasts with the Sensex’s 0.69% loss. The one-day performance saw a slight dip of 0.11%, marginally underperforming the Sensex’s 0.13% gain. This recent volatility suggests investors are weighing near-term factors carefully — is this a genuine recovery or a relief rally that will fade at the 50 DMA? — the moving average configuration provides the clearest answer.

Moving Average Configuration: Bullish Across All Key Averages

Technically, Sun Pharmaceutical Industries Ltd is trading above all major moving averages — the 5-day, 20-day, 50-day, 100-day, and 200-day. This comprehensive positioning indicates a strong upward trend and suggests the stock is in a sustained recovery phase rather than a short-lived bounce. The fact that the stock hit a new 52-week and all-time high of ₹1,987.7 today further reinforces this positive technical momentum.

Moreover, the stock has recorded gains for two consecutive days, rising 2.41% in this period. This short-term strength, combined with the long-term moving average support, signals robust investor confidence in the stock’s trajectory. However, the slight one-day decline reminds that volatility remains a factor to monitor closely.

Sector Context: Pharmaceuticals & Biotechnology Showing Mixed Results

The Pharmaceuticals & Biotechnology sector has seen a balanced set of results recently, with four stocks declaring results: two positive and two flat, and none negative. This mixed outcome suggests a sector in cautious equilibrium, where individual stock performance is likely to be driven by company-specific factors rather than broad sector tailwinds or headwinds.

Within this environment, Sun Pharmaceutical Industries Ltd stands out for its consistent outperformance relative to the Sensex and its peers. The stock’s ability to maintain a premium valuation despite sector-wide mixed results highlights its relative strength and resilience — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Rating Context: Previously Rated Hold, Now Reassessed

MarketsMOJO had previously assigned a Hold rating to Sun Pharmaceutical Industries Ltd. This rating was updated on 8 June 2026, reflecting a reassessment of the company’s fundamentals, valuation, and technicals. The current Mojo Score stands at 72.0, indicating a positive overall assessment, though the precise rating is not disclosed.

The rating update coincides with the stock reaching new highs and maintaining a premium valuation, suggesting that the reassessment took into account the company’s improved performance and technical strength. This change invites investors to consider the implications of the updated view — what is the current rating for Sun Pharmaceutical Industries Ltd?

Long-Term Performance: Strong Gains Over Multiple Years

Examining longer-term returns, Sun Pharmaceutical Industries Ltd has delivered robust gains. Over three years, the stock has appreciated 73.27%, significantly outperforming the Sensex’s 16.29% rise. The five-year return is even more impressive at 186.73%, compared to the Sensex’s 46.70%. However, the ten-year return of 139.31% trails the Sensex’s 172.74%, reflecting some periods of relative underperformance in the distant past.

This long-term data underscores the company’s capacity for sustained growth, though it also highlights the importance of recent years in driving overall returns. The current premium valuation and technical strength appear to be supported by this historical performance context.

Conclusion: A Data-Driven Portrait of Strength and Caution

The data on Sun Pharmaceutical Industries Ltd reveals a stock that commands a modest valuation premium in a mixed sector environment, supported by strong medium- and long-term performance and a bullish technical setup. The recent rating reassessment from Hold reflects these positive developments, though short-term volatility and sector uncertainties remain factors to watch.

Investors analysing this stock must weigh the premium valuation against the demonstrated ability to outperform the Sensex and maintain technical momentum — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today